Achaogen Awarded $4.5M NIAID Contract

Achaogen, Inc. has been awarded a contract for $1.5 million from the National Institute of Allergy and Infectious Diseases (NIAID), with additional funding of as much as $3.0 million during the next three years if all options are exercised.
 
The contract will specifically fund the discovery and development of LpxC inhibitors, which are novel small molecule agents, for the treatment of bacterial infections, including those resistant to currently available antibiotics. Achaogen’s LpxC inhibitor program is currently in the preclinical development.
 
“We are extremely pleased to receive this contract and are grateful for the opportunity to continue working with NIAID to address the global concern of antibiotic resistance,” commented Kenneth Hillan, chief executive officer of Achaogen.
 
LpxC inhibitors have the potential to fill an important unmet medical need in the treatment of infections such as bacterial pneumonias and bloodstream infections, and additionally have the potential to treat infections caused by biothreat pathogens.